Dynamic Technology Lab Private LTD Fibrogen Inc Transaction History

Dynamic Technology Lab Private LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$15.95 - $25.18 $395,544 - $624,438	24,799 New	24,799 $463,000
Q2 2022 Aug 12, 2022	BUY	$7.94 - $12.96 $363,056 - $592,596	45,725 New	45,725 $483,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $455,545 - $636,324	-37,899 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $376,337 - $583,265	37,899 New	37,899 $534,000
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $220,017 - $422,736	-11,848 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$31.0 - $55.72 $367,288 - $660,170	11,848 New	11,848 $411,000
Q4 2020 Feb 11, 2021	SELL	$37.09 - $48.97 $191,161 - $252,391	-5,154 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $208,582 - $234,507	5,154 New	5,154 $212,000
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $164,057 - $259,325	-4,670 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$42.83 - $59.91 $200,016 - $279,779	4,670 New	4,670 $254,000
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $250,676 - $362,615	-5,583 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $253,189 - $344,191	5,583 New	5,583 $258,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.